ArticleJournal of internal medicine2020
Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden.
Article in Journal of internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review.Cancer imaging : the official publication of the International Cancer Imaging Society · 2021Pooled it
- Telehealth-Delivered Dietary Counseling in Myeloproliferative Neoplasms: A Randomized Feasibility Study.Nutrients · 2026Trial
- Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial.International journal of hematology · 2024Trial
- [Progress in the study of polycythemia vera in children].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Review
- [Comparative study of the prognostic value of survival prognostic scoring systems in patients with essential thrombocythemia: IPSET, MIPSS-ET, AAA, and AAA].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Diagnostic and prognostic biomarkers in heart failure and myeloproliferative neoplasms: clinical applications and risk scores - a narrative review.Cardio-oncology (London, England) · 2026Review
- Modern and multidisciplinary care in polycythemia vera.Annals of hematology · 2026Review
- Loss of life expectancy in patients with myeloproliferative neoplasms in Sweden.Haematologica · 2026Article
- Validity of The Danish National Chronic Myeloid Neoplasia Registry.Clinical epidemiology · 2026Article
- Age- and gender-based frequency and association of common myeloproliferative mutations in a South African cohort.African journal of laboratory medicine · 2026Article
- Intersecting Pathways: The Impact of Philadelphia-Negative Chronic Myeloproliferative Neoplasms on the Pathogenesis and Progression of Heart Failure with Preserved Ejection Fraction.Diagnostics (Basel, Switzerland) · 2025Article
- Topics of Interest in Women With Myeloproliferative Neoplasms.American journal of hematology · 2025Review
- Polycythaemia vera.Nature reviews. Disease primers · 2025Review
- Management of Bleeding, Thrombotic and Pregnancy-Related Complications in Women with Myeloproliferative Neoplasms: A Case-Based Review Focusing on Sex-Specific Challenges.Journal of clinical medicine · 2025Review
- Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications.Current hematologic malignancy reports · 2025Review
- Cost-utility analysis of ropeginterferon alfa-2b to manage low-risk patients with polycythemia vera as compared to phlebotomy only in the Austrian healthcare system.Annals of hematology · 2025Article
- Prevalence, incidence, and thromboembolic events in polycythemia vera: a study based on longitudinal German health claims data.Annals of hematology · 2025Observational
- Cardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms: Mechanisms and Implications-A Narrative Review.Current issues in molecular biology · 2024Review
- Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature.British journal of haematology · 2024Review
- Childbirth rates in women with myeloproliferative neoplasms.Leukemia · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 3 countries.
Funding
Abstract
backgroundThe reported incidence of Philadelphia-negative myeloproliferative neoplasms (MPNs) differs substantially between previous reports, likely due to true regional differences in incidence and/or variations in the quality and coverage of the cancer registers.
objectiveWe therefore assessed MPN incidence in Sweden during recent years using prospectively collected information captured in Swedish health registers.
methodsPatients with MPNs were identified through the Swedish Cancer Register and Swedish Blood Cancer Register between 2000 and 2014. Information on the Swedish population was obtained from the Human Mortality Database. Crude and age-standardized incidence rates of MPNs with 95% confidence intervals (CIs) were calculated.
resultsA total of 6281 MPN cases were reported to the Swedish Cancer Register and Swedish Blood Cancer Register during 2000-2014. The age-standardized, to the Swedish population in 2000, incidence for all MPNs was 4.45 (95% confidence interval [CI] 4.34-4.56)/100 000 person-years. The age-standardized incidence for polycythemia vera was 1.48 (1.42-1.54), for essential thrombocythemia 1.60 (1.53-1.66) and for primary myelofibrosis 0.52 (0.48-0.56)/100 000 person-years, respectively. The incidence rate of MPNs was substantially higher in the older compared to the younger age groups. The incidence increased during the study period, likely to do better reporting and increasing age of the general population.
conclusionThe reported MPN incidences in our study, which were in the higher interval of previously published studies, are likely more accurate compared to previous reports due to the population-based setting and high level of coverage in the Swedish Cancer and Blood Cancer Registers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.